
Non-Mortgage Delinquencies Reach Levels Not Seen Since 2009
– 1.4 million people in Canada missed a credit payment as refinancing and renewals dominate the Q1 Mortgage market –
Equifax Canada Market Pulse Quarterly Consumer Credit Trends and Insights
TORONTO, May 27, 2025 (GLOBE NEWSWIRE) — Economic uncertainty continued to impact credit usage and consumer financial health across Canada during the first quarter of 2025 according to Equifax® Canada's latest Market Pulse Consumer Credit Trends and Insights. Total consumer debt in Canada was $2.55T at the end of Q1, up four per cent year over year, but down more than $6B from the end of 2024. Average non-mortgage debt per consumer rose to $21,859 in Q1 2025, primarily driven by a strong auto loan market as buyers looked to lock in purchases before anticipated price hikes.
'We often observe seasonal changes in credit usage during the first quarter. Generally speaking in the spring, we tend to see mortgage debt rising, however for Q1 2025 we saw mortgage debt levels fall compared to last quarter,' said Rebecca Oakes, Vice President of Advanced Analytics at Equifax Canada.' Despite a slowdown in demand for non-mortgage debt, overall balances remained fairly flat, an indication that consumer payment levels may be falling.'
Card spending slows but balances continue to rise
After experiencing high numbers for new credit card openings in 2023 and 2024, the first quarter of 2025 saw a 10.3 per cent decline in new card originations. Consumers that have lower credit scores accounted for an increase in new card openings, potentially indicating heightened credit reliance and financial strain in this consumer group.
Average monthly credit card spend1 per card holder fell by $107 dollars during Q1, dropping to the lowest level since March 2022. Ontario, British Columbia, Prince Edward Island, Nova Scotia and Yukon saw the biggest pull back in spending, dropping between six and seven per cent compared to the prior year.
'A drop in credit card spending when combined with increased payment amounts can imply improving financial conditions of consumers,' said Oakes. 'Our data shows card payment levels, especially for younger consumers, are starting to fall, indicating this spending slowdown is likely driven more by consumers trying to be prudent rather than switching from credit to debit for financing.'
The average credit card pay rate2 decreased to 52.9 per cent in Q1, down 32 basis points. Notably, younger consumers (under 35 years old) showed a more dramatic shift, with their average pay rate falling 392 basis points from 62.9 per cent to 58.9 per cent. This same group also exhibited the greatest increase in the level of minimum payers, rising 25 basis points year-over-year.
Mortgage growth driven primarily by renewals and refinancing
New mortgage originations jumped 57.7 per cent year-over-year in Q1 2025, but much of this activity stemmed from renewals and refinancing. This reflects the onset of the so-called 'Great Renewal,' as a wave of pandemic-era mortgages come up for renewal.
Renewal and refinancing activity surged, particularly in Ontario, Alberta, and B.C., with an estimated 28 per cent of mortgages switching lenders as Canadians shop around and seek better rates. Almost half of those switching (46 per cent) moved between the 'Big Five' banks, reflecting intense competition among major lenders.
'The shift in the mortgage market is clear - this is currently about existing homeowners navigating a complex refinancing environment,' added Oakes. 'But even as some find relief, affordability challenges haven't eased for everyone.'
First-time homebuyers returned to the market, with activity up 40 per cent from Q1 2024. Affordability remained a hurdle and while average monthly payments dropped by 7.8 per cent to $2,300, the average loan size increased by 7.5 per cent year-over-year.
Debt divide deepens as missed payments rise for some
While some consumers showed signs of prudence in their spending choices during the first quarter, missed payments continued to rise across most credit products. In total, more than 1.4 million consumers (1 in 22) missed at least one credit payment during the quarter.
Although mortgage holders experienced some stabilization thanks to steady interest rates, financial strain remained acute for non-mortgage consumers. Consumer level delinquency rates among non-mortgage holders rose 8.9 per cent year-over-year, compared to 6.5 per cent for mortgage holders. Younger Canadians were hit hardest, with the 18–25 age group experiencing a 15.1 per cent increase in delinquency rates.
Ontario consumers under stress
Ontario continued to remain a hotspot for financial stress in Canada, experiencing the most pronounced increase in delinquency rates across all credit products. Ontario's 90+ day mortgage delinquency rate rose to 0.24 per cent, a substantial 71.5 per cent increase since Q1 2024. British Columbia followed with a notable rise of 33.3 per cent, reaching 0.18 per cent, while the rest of Canada (excluding these two provinces) showed a comparatively modest increase of 3.3 per cent, reaching an average of 0.19 per cent overall.
Ontario also led the rise in non-mortgage delinquencies, up 24 per cent year-over-year, followed by Alberta at 15.9 per cent and Quebec at 13.9 per cent.
Significant increases for younger consumers and auto loans
The highest credit card 90+ day delinquency rates were observed among younger consumers under the age of 26, at 5.38 per cent, a significant 21.7 per cent increase year-over-year for this group. Overall, this rate stood at 3.76 per cent, marking a 15.8 per cent increase.
Auto loans followed a similar trend, with the delinquency rate for younger consumers rising by 30 per cent to 1.95 per cent, compared to an overall rate of 1.08 per cent, which represented a 15.3 per cent increase.
'We're observing positive shifts in consumer behaviour, with reduced credit card usage and early signs of delinquency stabilization for some consumers. However, headwinds will likely persist, such as rising unemployment and rising food prices, in already strained regions,' concluded Oakes.
Age Group Analysis – Debt & Delinquency Rates (excluding mortgages)
Major City Analysis – Debt & Delinquency Rates (excluding mortgages)
Province Analysis - Debt & Delinquency Rates (excluding mortgages)
* Based on Equifax data for Q1 2025
About Equifax
At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employers, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by nearly 15,000 employees worldwide, Equifax operates or has investments in 24 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit
Equifax.ca
.
Contact:
Andrew Findlater
SELECT Public Relations
afindlater@selectpr.ca
(647) 444-1197
Angie Andich
Equifax Canada Media Relations
MediaRelationsCanada@equifax.com
1 average spend comparisons have been adjusted for inflation
2 pay rate = payments / last months balance
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
StopTheBleed.com Launches As A Dedicated Resource for Bleeding Control Kits
LELAND, N.C., June 12, 2025 /PRNewswire/ -- In recognition of the 10th anniversary of the STOP THE BLEED® initiative, Rescue Essentials is proud to announce the launch of a streamlined e-commerce destination for officially licensed STOP THE BLEED® kits and mass casualty response solutions. Designed to help organizations of all sizes prepare for bleeding emergencies, provides expertly curated kits for schools, public buildings, factories, offices, and anywhere else traumatic bleeding can happen. Each kit is built at our North Carolina facility with trusted components from Rescue Essentials and other leading manufacturers such as SAM Medical and North American Rescue " makes it easier than ever for people to find the exact bleeding control kits they need, whether to comply with local legislation or simply to be better prepared," said Jim Seidel, Rescue Essentials CEO. "Our team is here to assist with product selection, identify applicable state requirements, and even help customers locate available grant funding to support their preparedness goals." As a licensed partner of the U.S. Department of Defense's STOP THE BLEED® program, Rescue Essentials is committed to supporting this international public health initiative, which empowers bystanders to take action and save lives in the critical moments following a traumatic injury. represents Rescue Essentials' continued dedication to delivering high-quality, accessible medical response products and training support to first responders, safety officials and everyday heroes across the country. About Rescue Essentials Since 2007, Rescue Essentials has remained focused on its original goal — to offer top quality tactical, emergency, combat, and outdoor medical products at affordable prices, delivered in a timely manner. Rescue Essentials' core capabilities include the design, manufacture, and assembly of purpose-built trauma and medical kits for law enforcement, EMS and government agencies. Rescue Essentials, a division of Tri-Tech Forensics, Inc., is based in Leland, N.C. View original content to download multimedia: SOURCE Tri-Tech Forensics

Yahoo
23 minutes ago
- Yahoo
Peter Vermeulen Reports Early Warning Report in respect of Infinico Metals Corp. (TSXV: INFM)
UTRECHT, Netherlands, June 12, 2025 (GLOBE NEWSWIRE) -- Peter Vermeulen announces that as a result of becoming the sole executive director of the fund manager for Stichting Legal Owner Plethora Private Equity ('Plethora'), he owns or controls an aggregate of 19,065,809 common shares ('Shares') in the capital of Infinico Metals Corp. ('Infinico') and 3,442,098 Share purchase warrants ('Warrants'), representing 28.03% of the Company's issued and outstanding Shares on an undiluted basis and 31.49% on a partially diluted basis. Prior to becoming the sole executive director of Plethora, Mr. Vermeulen owned 989,834 Shares, representing 1.46% of the Issuer's issued and outstanding common shares on both an undiluted and partially diluted basis. In satisfaction of the requirements of National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, an early warning report respecting the acquisition of securities by Plethora will be filed under the Company's SEDAR+ Profile at Mr. Vermeulen's holdings in Infinico have been established for investment purposes. Depending on market and other conditions, Mr. Vermeulen may from time to time in the future increase or decrease their ownership, control or direction over securities of Infinico, through market transactions, private agreements, or otherwise. Plethora is incorporated under the laws of the Netherlands and its head office is located at Maliebaan 50B, 3581 CS, Utrecht, The Netherlands. The principal business of Plethora is a Management Fund. For information regarding Plethora, please contact: Peter Vermeulen - Fund Manager Maliebaan 50B3581 CSUtrecht, The Netherlands Phone: +3 16 13 01 17 60 No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained in to access your portfolio

Associated Press
39 minutes ago
- Associated Press
BioNxt Solutions Provides Bi-Weekly MCTO Status Report
VANCOUVER, BC / ACCESS Newswire / June 12, 2025 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT), announces that, further to its news release dated May 1, 2025 (the 'Default Announcement'), the Company's principal regulator, the British Columbia Securities Commission (the 'BCSC') granted a management cease trade order (the 'MCTO') on May 1, 2025, under National Policy 12-203 Management Cease Trade Orders ('NP 12-203"). Pursuant to the MCTO, the Chief Executive Officer and the Chief Financial Officer may not trade in securities of the Company until such time as the Company files its annual audited financial statements for the year ended December 31, 2024, including the related management's discussion and analysis, and CEO and CFO certifications on or before June 30, 2025 (collectively the 'Required Documents') and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities. The Company's staff are working diligently with its auditors and the Company anticipates that it will be in a position to file the Required Documents by June 30, 2025. All previously outstanding audit materials related to the Company's German subsidiaries are now in-hand and the consolidations model is complete. Draft financials have been prepared and provided to the Company's audit firm. The Company's Board of Directors and management confirm that they are working expeditiously to file the Required Documents and confirm that since the Company's Default Announcement: Until the Required Documents have been filed, the Company intends to continue to satisfy the provisions of the Alternative Information Guidelines specified in NP 12-203 by issuing these bi-weekly default status reports in the form of further press releases for so long as the Company remains in default of the Required Documents filing requirement. About BioNxt Solutions Inc. BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide. BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit Investor Relations & Media Contact Hugh Rogers, Co‐Founder, CEO and Director Email: [email protected] Phone: +1 778.598.2698 Web: LinkedIn: Instagram: Cautionary Statement Regarding 'Forward‐Looking' Information This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'may,' 'could,' 'will,' 'plans,' and similar expressions. These statements relate to future events or future performance, including, but not limited to, statements regarding the anticipated timing for filing the Required Documents, the Company's ability to remedy its filing default, the expected revocation of the MCTO, and the Company's continued compliance with National Policy 12-203 Management Cease Trade Orders ('NP 12-203"). Forward-looking statements are based on the Company's current expectations, beliefs, and assumptions, including assumptions regarding the timely completion of the audit process, the ability of the Company and its auditors to meet required filing deadlines, the accuracy of management's estimates and expectations, regulatory approvals, and market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include, but are not limited to: delays in the audit process; the Company's inability to file the Required Documents within the anticipated timeframe; regulatory or compliance issues; changes in financial reporting or disclosure standards; unanticipated requests for additional information from auditors or regulators; and other unforeseen financial, operational, or regulatory developments. Additional risk factors are outlined in the Company's public filings available on SEDAR+ ( ). The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements, as actual results may differ materially from expectations. SOURCE: BioNxt Solutions Inc. press release